Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · April 07, 2023

ELCC 2023: Nivolumab + Chemotherapy Shows Continuous Benefit in NSCLC Versus Chemotherapy Alone

Three-year results from the CheckMate 816 study show event-free survival of 57 percent versus 43 percent with chemotherapy alone

PracticeUpdate Editorial Team

 

Further Reading